Literature DB >> 18302268

Differential expression of MUC1 and carbohydrate antigens in primary and secondary head and neck squamous cell carcinoma.

María V Croce1, Martín E Rabassa, Adrián Pereyra, Amada Segal-Eiras.   

Abstract

BACKGROUND: In head and neck squamous cell carcinoma (HNSCC), tumor markers may be helpful to evaluate prognosis accurately as well as to improve therapy selection. Detection of human MUC1 has been widely employed for the evaluation of carcinoma patients. This article aims to study MUC1, Tn, sTn, and Lewis antigenic expression in primary HNSCC, lymph node metastasis, and local recurrences.
METHODS: We used immunohistochemistry, tissue homogenization and differential centrifugation, isopycnic density gradient centrifugation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and Western blot.
RESULTS: In primary tumors, MUC1 was detected in 80.0% of the samples; sLewis x in 23.2%, Lewis x in 45.6%, and Lewis y in 40.8%. Tn and sTn were found in 4.0% and 6.4% of samples, respectively. In metastatic lymph nodes, MUC1 showed a similar positive reaction as in primary tumors. Lewis y was detected in 20% lymph nodes whereas Lewis x, sLewis x, Tn, and sTn did not show differences. Some recurrences expressed MUC1 and only a few Lewis antigens, whereas Tn and sTn were not detected.
CONCLUSION: In primary HNSCC and metastatic nodes, a high expression of MUC1 and Lewis antigens was detected that diminished in local recurrences. We also found that differentiated tumors mainly expressed a linear pattern of MUC1CT and Lewis x.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18302268     DOI: 10.1002/hed.20756

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  9 in total

1.  MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.

Authors:  V Genitsch; I Zlobec; G N Thalmann; A Fleischmann
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-10       Impact factor: 5.554

2.  Lewis x Antigen is Associated to Head and Neck Squamous Cell Carcinoma Survival.

Authors:  Martín E Rabassa; Adrian Pereyra; Liliana Pereyra; Amada Segal-Eiras; Martín C Abba; Maria V Croce
Journal:  Pathol Oncol Res       Date:  2017-07-05       Impact factor: 3.201

Review 3.  Regulation of the metastatic cell phenotype by sialylated glycans.

Authors:  Matthew J Schultz; Amanda F Swindall; Susan L Bellis
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

Review 4.  What role do mucins have in the development of laryngeal squamous cell carcinoma? A systematic review.

Authors:  Fabian Sipaul; Martin Birchall; Anthony Corfield
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-28       Impact factor: 2.503

5.  Potential ferroptosis-related diagnostic and prognostic biomarkers in laryngeal cancer.

Authors:  Zao Ji; Zhiyao Fang; Xue Dong; Jia Wang; Xianyao Wan; Aihui Yan
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-12       Impact factor: 3.236

6.  Clinicopathological and prognostic significance of sialyl Lewis X overexpression in patients with cancer: a meta-analysis.

Authors:  Jin-Xiao Liang; Yong Liang; Wei Gao
Journal:  Onco Targets Ther       Date:  2016-05-24       Impact factor: 4.147

7.  Expression of MUC1 mucin in potentially malignant disorders, oral squamous cell carcinoma and normal oral mucosa: An immunohistochemical study.

Authors:  M Harish Kumar; Karpagaselvi Sanjai; Jayalakshmi Kumarswamy; Roopavathi Keshavaiah; Lokesh Papaiah; S Divya
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug

8.  Prognostic and clinicopathological significance of MUC expression in head and neck cancer: a systematic review and meta-analysis.

Authors:  Hao Lu; Dan Liang; Yun Zhu; Wanlin Xu; Kaihua Zhou; Limin Liu; Shengwen Liu; Wenjun Yang
Journal:  Oncotarget       Date:  2017-07-27

9.  The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.

Authors:  Donald T Weed; Serena Zilio; Isildinha M Reis; Zoukaa Sargi; Marianne Abouyared; Carmen R Gomez-Fernandez; Francisco J Civantos; Carla P Rodriguez; Paolo Serafini
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.